ALK inhibitors (Positive control) and ABT199 (Proposed binding) in complex with the ALK active side. by Richard Junior Zapata Dongo (17912565)

Subjects:

Comparative Analysis of Hela Cells Cultured under Static Conditions and Exposed to Fluid Shear Stress. by Xinyao Zhao (5824427)

Subjects:

Visualization of immune cell infiltration between AD and control group. by Wei He (131453)

Subjects:

BCL2 protein keeps their expression in different conditions treatment nevertheless each EML4-ALK cell modells exhibit variable expression. by Richard Junior Zapata Dongo (17912565)

Subjects:

Combination therapy exhibited apoptosis in Ba/F3 EML4-ALKmutant cell models. by Richard Junior Zapata Dongo (17912565)

Subjects:

miR-1247-3p was downregulated in CRC resistant cells. by Dequan Wang (6007007)

Subjects:

The binding energy values of ATP, ALK inhibitors and ABT-199 to ALK were obtained from AlphaFold and modeled protein structures. by Richard Junior Zapata Dongo (17912565)

Subjects:

Downregulation of miR-1247-3p inhibited apoptosis and reduced chemosensitivity in cells. by Dequan Wang (6007007)

Subjects:

Loewe synergy-antagonism score analysis shows additive and synergistic effects after ALKi and ABT-199 combination treatment. by Richard Junior Zapata Dongo (17912565)

Subjects:

miR-1247-3p was downregulated in tissues of patients with CRC and was associated with prognosis and drug resistance. by Dequan Wang (6007007)

Subjects:

Overexpression of miR-1247-3p promoted apoptosis and inhibited resistance in drug-resistant cells. by Dequan Wang (6007007)

Subjects:

Amino acids interactions and binding energy describe that ABT-199 binds to ALK^Mutant. by Richard Junior Zapata Dongo (17912565)

Subjects:

BCL2 antiapoptotic protein exhibits heterogeneous expression in Ba/F3 EML4-ALK^mutants. by Richard Junior Zapata Dongo (17912565)

Subjects:

Ba/F3 EML4-ALK^mutants exhibit variable dose-response to ABT-199 treatment. by Richard Junior Zapata Dongo (17912565)

Subjects:

Molecular docking showed that ABT-199 can fit into active site of ALK^Mutant. by Richard Junior Zapata Dongo (17912565)

Subjects:

PBM significantly reduces hyperphosphorylation of tau with no effect on total tau expression. by Kevin J. Johnson (2647639)

Sociodemographic characteristics of participants at baseline, overall and by age group. by Chelsea S. Lutz (16001569)

Subjects:

Clinical outcomes and COVID-19 treatment during acute illness, by hospitalization status and age group. by Chelsea S. Lutz (16001569)

Subjects:

Symptoms self-reported and/or documented in the electronic health record during the acute COVID-19 illness, by hospitalization status and age group. by Chelsea S. Lutz (16001569)

Subjects:

Sociodemographic and clinical characteristics associated with PCC at three months post-acute illness among adults enrolled during Omicron predominance. by Chelsea S. Lutz (16001569)

Subjects: